Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Camurus, Audiocast, Q2'25

By Inderes7/17/2025, 12:00 PM
Camurus

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Fredrik Tiberg
00:00 - 01:53

Thank you, Anna, and hello everyone. Welcome to our second-quarter earnings call. And here are our forward-looking statements. So the agenda for our call today is a summary of highlights in the quarter followed by financial and commercial performance reviews, then an update on the pipeline and business development before finishing off with Q&A. With me to provide the financial update is Jon Garay, CFO. Also present are Richard Jameson, Chief Commercial Officer, and Andrew Schwartz, incoming CFO. So Camurus had a successful second quarter with good performances across our business. Financially, we delivered all-time record revenues and high profitability, further strengthening our cash position for planned expansions and pipeline investments. And on the corporate side, we entered a strategically important license agreement for long-acting innovations with Eli Lilly, a world leader in cardiometabolic diseases. Commercially, our teams continued executing growth in Europe and the rest of the world, regaining momentum after a quiet first quarter. Of course, the EU approval of vaccines for the treatment of acromegaly was a clear highlight, which is now the first of a new generation of products based on our innovative FluidCrystal® technology. We also received positive results from the Positano study and the extension trials. So with this notable progress, I hand over to John for, um, actually his final review of our financial performance. So here. John.

Jon Garay
01:54 - 05:46

Yes, indeed, Fredrik. Thanks a lot, Fredrik, and good afternoon, everyone. Camurus delivered strong financial performance in Q2 and I would like to share the main highlights now. Camurus achieved 676 million total revenue in the quarter, delivering a 52% growth compared to the same period last year. Product sales reached 470 million SEK, growing 17% compared to the prior year, but declining 3% compared to the prior quarter. Swedish kronor appreciation impacted reported figures negatively by six points versus the prior quarter and nine points versus the same period. Prior year. Swedish kronor appreciation has impacted negatively. Royalty reported figures were negatively impacted by 11 points compared to the previous quarter. Company profit before taxes was 307 million SEK, representing 45% of sales and growing 195% compared to the prior year. Earnings per share after dilution was 4.08 Swedish kronor, equivalent to a profit after tax of 245 million SEK in the quarter. Finally, our cash position was 3.35 billion SEK at the end of the quarter. Moving to the next slide, we can see the main components of our profit before taxes. Company gross margin reached 93.9% in the quarter, representing an improvement of 106 basis points versus the same period prior year. The improvement was driven by two major factors. Firstly, the royalty and license revenue from the collaboration agreement with Lilly represented a 146 basis point increase. Positive impact and secondly, effects represented again a negative impact of 40 basis points in the quarter. No material variances occurred in the gross margin. Total opex reached 343 million SEK, growing 4% versus the same period the prior year, driven by the following factors: marketing and distribution investment to support market penetration in own territories, expansion of Mobile into new markets, and US operations grew 2% to 133 million SEK. Administrative expenses align with corporate evolution; consequently, company development grew 118% versus the prior year to 52 million SEK. R&D investment reached 151 million SEK, representing a 13% decline versus the same period prior year, driven by lower milestones in our ongoing clinical trials and the acromegaly study. Ramp down, company profit before taxes reached 307 million SEK, growing 195% versus the prior year, representing 45% of our sales. Company cash position was 3.35 billion SEK. Camurus improved its cash position by half a billion SEK in the second quarter, driven by two main factors. Firstly, company operations generated 349 million SEK, and secondly, a stock option program exercised by employees delivered 126 million SEK. Finally, other minor concepts are mainly legacy liabilities. The update represented a negative impact of 5 million SEK as at the end of the quarter, Camurus has no debt. All in all, Camurus closes the first half of 2025 with a solid financial position, interesting growth opportunities, and based on financial performance to date, the company maintains the full year guidance. Having said that, I would like to pass the word to Richard. Thank you, everyone, for your attention.

Richard Jameson
05:47 - 07:53

Thank you, John. So Buvidal continued to grow in Camurus markets, increasing 3% quarter on quarter and 26% year on year at constant exchange rates, with performance being led by Australia, Spain, and the Nordics. At the end of the period, we estimate about 65,000 patients were in treatment with Buvidal. Overall, sales are growing in accordance with internal expectations and are aligned with their contribution to our guidance. In the quarter, reported sales were affected by exchange rates, with a 6 percentage point impact and purchase order patterns from distributors and wholesalers, while in the UK, there was a short-term delay in committed funding reaching the clinics. As part of our expansion plans for Buvidal, we also initiated the launch in Portugal, which has nearly 20,000 patients in opioid dependence. Treatment. In the second quarter, our royalties on net sales grew 21% versus the first quarter, reaching 89 million SEK, an increase of 32% at constant exchange rates. The renewed growth reflects our US licensee Braeburn's continued execution and the easing of the first-quarter headwinds, including seasonal prescription authorizations and the impact of last year's cuts in federal funding in the criminal justice system. Braeburn expects Brixadi R&D to continue its growth in the coming quarters, supported by state-level initiatives to expand and improve access to opioid dependence treatments. And, of course, long-acting injectable buprenorphine. Furthermore, the federal medical assistance percentage for Medicaid seems to remain unchanged at current levels and the budget reconciliation bill exempts substance use disorder patients from the work requirements. So on that brief update, I'll hand back to Fredrik.

Fredrik Tiberg
07:54 - 19:43

Okay. Thank you, Richard. And then over to a pipeline update starting with CAM2029, which is under development for the treatment of acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease. So in the quarter, we were pleased to receive a positive opinion from the CMP recommending approval of the EU trade name for CAM2029 in acromegaly. This was followed by a final approval by the European Commission on the 30th of June for the indication of maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs. This is aligned with the product information of the current standard of care with standard statin and Sir Matthew Lean and provides a really good starting point for establishing access as a first-line treatment of acromegaly. So in preparation for the launch in the first EU markets estimated for early 2025, we have been actively meeting with stakeholders, including hosting advisory boards, engaging with payers, and preparing commercial and medical affairs readiness. And we have had a significant presence at key scientific meetings to accurately communicate our results and inform about our product, including at the European Society for Endocrinology meeting in Copenhagen in May and at last week's International Pituitary Society Congress and the annual meeting in San Francisco. Overall, we're getting excellent feedback. This has included both oral presentations and posters, as well as educational programs. In the quarter, we received new compelling results from an extension study of Nova two from a subset of patients that were treated for an additional 12 months with Cam 2029, totaling two years. And these patients constituted two different groups: those who continued treatment with Cam 2029 directly after finishing the actual Nova 2 main trial, illustrated on the left side, and patients who were invited to treatment with Cam 2029 after an intermediate period back on treatment with standard of care. The interesting thing with this study is that for both groups, clear improvements were seen in the response rate. IGF-1 below one times the upper limit of normal. After switching from standard of care to treatment with Cam 2029 for 2 or 1 years. Interestingly, as you can see on the right-hand side, a clear decrease in response rate was observed for re-invited patients when they were switched back to treatment with the standard of care following a period on Cam 2029. And then this was, of course, reversed going the other way. So the improvement that we see in the response rate may very well be related to the high titrate exposure provided by Cam 2029 and is, of course, promising and very interesting for other trials, including the serum study. As in previous studies, treatment with Cam 2029 also resulted in improvements in acromegaly symptoms and treatment satisfaction. Further emphasizing the potential benefits of the 2029 treatment for patients with acromegaly. Acromegaly. So in the quarter, we also received positive results from the Positano study in patients with polycystic liver disease. PLD is a rare genetic condition associated with the progressive growth of cysts in the liver that can cause a range of symptoms and reduce the quality of life of patients. There is currently no approved treatment available for these patients, so Camurus 2029 has orphan drug designation for isolated autosomal dominant polycystic liver disease in the US and Europe, and applications are also under review for PLD associated with polycystic kidney disease, which is the larger proportion of patients with this disease condition. The Positano study was a 53-week, randomized, placebo-controlled, three-arm study of two dose groups of Cam 2029 versus placebo in patients who had symptomatic polycystic liver disease. The primary endpoint was the relative liver volume change from baseline to week 53 between the combined Cam 2029 groups and the placebo. Secondary endpoints included total cyst volume, kidney volume change, polycystic liver disease symptoms, and quality of life scores, as well as pharmacokinetics and pharmacodynamics, including insulin growth factor 1 and safety, of course. So the study met the primary endpoint, showing a statistically significant relative reduction of the height-adjusted liver volume from baseline to week 53 of 4.3%, with a p-value of 0.044 for the combined groups versus placebo. This was also supported by sensitivity analyses. The time evolution of the liver volume change compared to placebo is shown in the figure on the right. Interestingly, in the study, we also measured the change in total liver cyst volume, which was suggested by the FDA as an alternative endpoint to total liver volume. This has, to our knowledge and to that of our investigators, not been assessed in previous polycystic liver disease trials, as can be seen in the graph on the left-hand side. The total liver cyst volume continued growing for 53 weeks in the patients on placebo, whereas it was stabilized in Cam 2029 treated patients. The relative change between Cam 2029 and placebo groups increased, and that's on the right-hand side, to a mean of -8.7% at week 53 in favor of Cam 2029 with a p-value of 0.016. So overall, we are really pleased with the outcome of the Positano study, which met the primary endpoint, as well as indicated other important outcomes, including cyst volume, and provided symptom improvements as measured by Camurus' own developed PLS questionnaire and other patient-reported outcome measures. We also saw a robust decrease of plasma IGF-1 levels with Cam 2029 versus placebo. The safety profile was consistent with that of other injectable somatostatin receptor ligands, and overall, both treatment and study retention were high in the trial, and all eligible patients chose to enter the two and a half year extension period after the core phase. So in summary, for CAMP 2029, significant progress was made during the quarter. In acromegaly, the EU approval of CSA was, of course, the highlight. The corresponding application in the US is ready for resubmission. Following the announcement of an upcoming routine GMP inspection of the third-party manufacturer by a national authority here in Q3, we have decided to appropriately await this inspection before submitting the NDA to the FDA. We believe the submission will be done during September for the Sorrento Phase three trial. Finally, as we have already alluded to in PLD, we are preparing for an end-of-phase two meeting with the FDA to discuss the design and registration of the phase three program for camp 2029 and polycystic liver disease. So, alongside the advances in the camp 2029 programs, we have progressed the Phase 1 study of our once monthly semaglutide formulation Camp 2056. In patients with overweight or obesity, the last patient visit is scheduled in the third quarter and results are expected in Q4. In addition, we have entered a strategically important collaboration. As noted before, a licensing agreement with Eli Lilly for the development and commercialization of long-acting initiatives in the cardiometabolic space was established. And this license agreement includes up to four Lilly proprietary compounds, which are then selected from one of three groups: dual GIP/GLP-1 receptor agonists, triple GIP/glucagon/GLP-1 receptor agonists, and an option to include receptor agonists. The agreement does not include our semaglutide development, which we intend to continue to develop separately from the Lilly collaboration. So in return for the agreement, Camurus is eligible for up to 290 million in license fees, development, and regulatory milestone payments. 580 million in sales-based milestone payments. And on top of that, a tiered mid-single-digit royalty on global net product sales. We are really delighted to enter into this agreement with Lilly and look forward to a productive and successful collaboration. To conclude, Camurus had an excellent quarter with record-high revenues. We received EU approval for our second commercial product, Oxy, in a new therapeutic area. We achieved positive results from both the Positano and the Nova extension studies, and signed a strategically important license agreement with Lilly. So with this, I would like to thank you all for listening and move over to Q&A. Um, now, can you please take over the call?

Jon Garay
19:43 - 19:54

Yes. Thanks, Fredrik. Uh, as a reminder, if you wish to ask a question, please press Pound Key five on your telephone keypad. The first question is from Christopher Wood from SEB. Please go ahead. Your line is open.

Richard Jameson
19:57 - 20:57

Uh. Hi there. Thanks for taking my questions. I have a few. So do you continue to expect an acceleration of growth over the remainder of 2025? And what can you tell us about the market dynamics in general and then, in particular, about why your market share of injectable buprenorphine has plateaued, and what steps can be taken to grow share again? Um, and you mentioned in the report that the decline in oral buprenorphine was a result of the growth in injectables. Uh, sorry, what my question is, did the oral buprenorphine decline come as a result of injectables growth only? Or were there other meaningful factors at play? Um, thanks. That's the first one.

Fredrik Tiberg
20:58 - 23:07

Uh. Thank you. Uh, well, I mean, overall in the US, I mean, I think the most important conclusion from, uh, this report is that, uh, growth is back in the US in terms of big cities. And it was, I think, a very strong quarter. Uh, we were not sure how quickly this would return, but we are pleased with the growth that we have seen in the second quarter. Of course, the reason for this, I think, is a combination, as I indicated in the report, of the headwinds being, you know, largely overplayed in terms of the seasonal authorizations. And the other points I raised in the previous quarter. And I think looking at the positive dynamics, there are a number of states that have, um, prioritized substance use disorder treatment. So I think that can certainly be one important component of the growth drivers. And that's where we can grow. Um, as regards to the share of the long-acting injectable space, I believe we have been in a static phase in Q1, and I think that will change over time. And I'm expecting to see continued growth in the segment as well. But I think that's the response I have. Any further comments from the team here? Yeah. Does that answer your questions, Christopher?

Richard Jameson
23:08 - 23:19

Yeah, that's great. Um, if I could ask then a quick one on. Yes, for acromegaly in Europe. How should we think about the early ramp up?

Fredrik Tiberg
23:20 - 23:42

So, I mean, we will follow, uh, a country-by-country approach similar to what we have done with. So, uh, we see a large interest in the market, but obviously this is a smaller indication. Um, the interest is very large. So, so, uh, but it will be a country by country approach.

Richard Jameson
23:45 - 24:05

Okay, great. And then, um, regarding Positano, what potential conferences are you considering submitting an abstract to? And have you seen any signs of a dose-response or differences between responses in ADP or DADP that you can kind of share?

Fredrik Tiberg
24:06 - 25:15

Um, well, when it comes to conferences, uh, there are not any really important conferences in the late autumn or winter period. So our focus will be on the main event of the year. Uh, it is EASL, and I think it will be in May next year. The abstracts are due. I mean, uh, I think early January. So that's going to be our focus for the main results from the study. Um, in terms of the response. We did not see a difference between the ADP CD patients and the ADP CD-associated PLD and the ADP LD patients. Of course, you have to consider the fact that this was a small study. So, you might need to involve larger numbers, but our analysis did not show any difference between those patient groups.

Richard Jameson
25:17 - 25:19

Okay. And you had two dose levels, right?

Fredrik Tiberg
25:20 - 25:47

Yes, and we will come to that. We will come into that later. In one parameter. There is a difference. But we need to further understand that. And whether or not it's more of a chance effect due to the small groups or if it is a real effect. But overall, it seemed to be a similar response between the two dose groups.

Richard Jameson
25:50 - 26:09

Got it. And then my last question would be just on the incretins. So what was your spreadsheet to CTA time, if I may phrase it that way? Um, for semaglutide, uh, how long ago did you expand the development work to include other ingredients?

Fredrik Tiberg
26:09 - 26:44

Oh, well, I mean, in terms of the process, we had a very rapid start to our pre-clinical program for semaglutide and the clinical trial. But I don't want to go into that. But it was a quick process. And I assume that you are alluding to or thinking about, you know, the next steps and so forth, but ideally, it can be done quite quickly.

Richard Jameson
26:47 - 26:50

Okay. I mean, should we be thinking, like a year or less or more?

Fredrik Tiberg
26:50 - 27:05

I don't want to give. I mean, because if you're trying to, you know, use that for our partners' timelines, I think it's better to report them once they occur. But, uh, I think.

Richard Jameson
27:05 - 27:06

Thank you so much.

Jon Garay
27:06 - 27:06

Much.

Fredrik Tiberg
27:06 - 27:07

Yeah, thank you.

Richard Jameson
27:09 - 27:14

The next question is from Susana, from San Juan. Please go ahead, Susana. Please go ahead, Susana. Your line is open.

Fredrik Tiberg
27:16 - 27:42

Hello. I want to ask a few questions regarding Buvidal. I noticed that you had 2,000 net additions of new patients in Q2. That's an average of 3,000 patients. And I think seasonally, Q2 is also expected to be quite strong. So perhaps starting with that. Maybe, Richard, you could say a few words about that.

Richard Jameson
27:43 - 28:12

Yeah, sure. Um, yeah. I mean, underlying demand remains strong, I think is the point to get across. I mean, it affected the quarter, as I mentioned, due to various factors including stock levels, the distribution by wholesalers, and their ordering patterns. And there was a short-term delay in the UK as the committed funding by the government hasn't reached the clinics yet, but we expect that in the next three quarters, and it would accelerate from there. So yes, it was a little light, but I think we'll catch up going forward.

Fredrik Tiberg
28:16 - 28:25

So this is the stocking effect and delay effect. It's not something representing a saturation of the market or something like that.

Richard Jameson
28:25 - 28:26

No, that's correct.

Fredrik Tiberg
28:29 - 28:51

Okay. As a follow-up question, I wanted to ask about the Eli Lilly deal. Going forward, what kind of ability will you actually have to share progress in this? Are we going to get any press releases, or is the new float completely owned by Eli Lilly?

Jon Garay
28:52 - 29:25

Well, I mean, we will report material developments as part of our obligations as a listed company. And that will be things, you know, relating to revenue streams as well as, you know, major clinical events, I would say. So we are expecting to be able to report continuously on more important events, but perhaps not on less significant ones.

Richard Jameson
29:31 - 30:02

Um, finally, on your, um, on your guidance that you haven't changed since the beginning of the year. Um, given the week of sales in Q1. Um, but now the upfront payment for the Eli Lilly deal. Um, you haven't made any revisions. How should we think about the second half of the year? Is there going to be a clear pickup from both, and how do you expect to reach your topline guidance?

Fredrik Tiberg
30:03 - 30:41

So I think it's important that we have stated, you know, and this is also the information we have received from our partner in the US, that we are expecting growth to continue in the third and fourth quarters. Uh, Richard just said that we are also expecting to see growth in the second half of the year, and both of these are, of course, key considerations when we have reviewed and updated our guidance. And they are major components of that.

Richard Jameson
30:44 - 30:45

Okay. Thank you.

Fredrik Tiberg
30:46 - 30:47

Thank you so much.

Richard Jameson
30:48 - 31:04

The next question is from Sean Homer from Jefferies. Please go ahead. Your line is open. Ah. He disappeared. So your line is open. Tick tock.

Fredrik Tiberg
31:05 - 31:35

Okay. Yeah. Yeah. Hi. Thanks for taking my question. Um, yeah. So a quick one maybe on Buvidal. Um, you mentioned the UK with a delay in funding. Um, will that be back already in Q3, or do you believe that it will linger on for some more quarters? Um, I don't really understand your answer to an earlier question. Uh, it would also be nice to get any update on Germany and that, uh, reimbursement situation as well. Thank you.

Richard Jameson
31:37 - 32:30

Yeah, sure. I mean, the government had committed the funding for treatment in advance for this coming year. And it really is just bureaucratic slowness causing the delay in moving money from government departments into the clinic. So that's why we're positive that it's going to change, and we expect it to come in the next three quarters because the NHS year runs from March to April, so we certainly expect to see a pick-up in the next two quarters of this year as that money comes in. Oh, in Germany? Yeah, Germany. We're progressing, and we still have the same remuneration challenge. But we know there's a movement. It's not something we're involved with, of course, but there's movement to try and resolve that issue. Um, there are ongoing pilots in a number of areas, so we're watching the space carefully regarding that. And, uh, we are expecting a resolution relatively quickly, hopefully.

Fredrik Tiberg
32:33 - 33:24

Okay. Thank you. And also a question here on the Lilly deal. I know you can't disclose too much around this, but I just want to get some more details about how this deal materialized. Did you speak to other parties here before this deal was done? And also in terms of the upfront? Um, at face value, you know, it's a great deal, but it just looks like the upfront is quite small compared to other deals done in this space. So any comment you can give on the rationale of the financial structure of this deal regarding the upfront payment versus the longer-term milestone dynamic? Um, that's because of the sales potential royalties that could come up from this in the future. Is that what attracted you and made you structure the deal the way you did? Uh, rather than demanding a bigger upfront payment, etc.? I just wanted to get some more details there, if it's possible. Thanks.

Jon Garay
33:24 - 34:11

Yeah, sure, sure. Uh, I mean, regarding the financials. First of all, on the financials, I can say that we focus on other things rather than the short term. Our financial situation is, uh, as you see, strong. So, we have focused on other aspects of the transaction. Um, so that's the main reason for the milestones. When it comes to other discussions, unfortunately, I cannot comment. As you understand, I cannot comment on that, but we are very pleased with the structure of the transaction that we have now. And because it fulfills our purpose with the deal. I can't say more than that.

Richard Jameson
34:13 - 34:57

Okay. Yep. I fully understand. And also, I had a final question. Um, I guess the market now, um, sees a bit more of your platform potential after the Lilly deal. Um, so I just wanted to ask a quick question about your program with your gonadotropin-releasing hormone agonist using FluidCrystal®. What's the next step here? Uh, what's the opportunity in terms of perhaps market size, unmet need, etc.? Um, especially in comparison with other current long-acting formulations? Um, you know, CV has, you know, every six-month administration with a loop in this space, etc.

Fredrik Tiberg
34:57 - 34:58

I don't think I.

Richard Jameson
34:58 - 34:59

I mean, any comment there would be helpful.

Fredrik Tiberg
35:00 - 35:10

Yeah. To be quite frank, it's not the focus area for us right now. It's more of an opportunistic approach to that. We have other developments that are prioritized.

Richard Jameson
35:13 - 35:23

Okay. Um, so any comments on what's next, do you think in line after, you know, the programs that you have in focus here that you are prioritizing?

Fredrik Tiberg
35:24 - 35:38

We will come up with that, uh, at our upcoming meetings. So we will certainly prioritize that in the short term, but it is not the time for those announcements today.

Richard Jameson
35:41 - 35:42

Okay. Thank you very much.

Fredrik Tiberg
35:42 - 35:45

Thank you very much.

Richard Jameson
35:46 - 35:50

Uh, Sean Homer from Jefferies, please go ahead. Line is open.

Fredrik Tiberg
35:53 - 36:19

Hi. Thank you. Just a few for me, please. Um, so I believe if I remember correctly, the aim was to have over 100,000 Buvidal-treated patients by 2027. Obviously, you're currently at 65,000. Um, so that requires sort of a bit of a step up. Um, if by 2027 means at the beginning of that year, which countries can we expect to actually drive this acceleration? And then what is the potential for a methadone switch? So that's my first question.

Jon Garay
36:19 - 36:21

Yeah, I think I'll leave that question to Richard.

Richard Jameson
36:22 - 37:25

Yeah, I believe it's a good question. Um, our ambition still remains for 100,000 patients by the end of 2027. Um, clearly, we're working across the major geographies to try and address the funding and improve access to Buvidal. But I think what's clear is the benefit that it's bringing to patients, families, and society. And there's no doubt that it's continuing to build demand for the product. Um, and that includes demand from the methadone segment as well. Um, you know, we hadn't seen that with sublingual necessarily, but we have certainly seen with Buvidal that patients are interested in moving over, because of the benefits that long-acting preparations confer to patients. And we're very active at the moment supporting clinics on how to transfer. It's not such an easy transfer from sublingual, but we're supporting that through medical education and ongoing programs to help. I talked about Portugal. That's a big opportunity for us. Um, so yeah, the 100,000 still remains our ambition. Certainly still achievable. Um, and we have some plans to try and address the hurdles that are preventing that.

Jon Garay
37:27 - 37:30

Brilliant. Thank you. And that was by the end of 2027.

Richard Jameson
37:30 - 37:31

Thank you. But.

Jon Garay
37:32 - 37:43

Okay, great. Um, and then just on Brixadi. So, um, where do you stand in terms of long-acting injectable buprenorphine market share versus your peers?

Fredrik Tiberg
37:45 - 38:17

Well, I mean, uh, the last time we actually announced market share. And we'll see. So, we haven't made any further developments there or talked about it. So, so um, and that was, I think, at the end of Q4 in the Q4 report.

Jon Garay
38:20 - 38:39

Understood. Thank you so much. And then just finally, um, considering your strengthened cash position, particularly with the Lilly up front, has that increased your appetite for M&A, or is the focus on preserving optionality and reinvesting within the pipeline?

Fredrik Tiberg
38:40 - 39:16

We are very active on the BD side and looking at different target opportunities. We are not looking to be a serial acquirer, but we are definitely working hard on that. And I think there are interesting opportunities. However, they will not be communicated until they have been settled, so to speak. So, so, um, but but we have a very active agenda. Ongoing.

Jon Garay
39:19 - 39:21

Got it. Thank you so much. That's all for me.

Richard Jameson
39:22 - 39:26

The next question from Oscar Hoffman. Lamb from Stifel. Please go ahead. Your line is open.

Fredrik Tiberg
39:31 - 39:51

Thank you. My question. Um, so my question would be, you know, how should we think in terms of forex for H2? Uh, so basically, you know, what type of impact are you seeing based on the current exchange rates? And then maybe as a follow-up. What was the exchange rate you did use for the current guidance? Thank you.

Jon Garay
39:52 - 41:17

So I mean, in terms of the second half of the year, we are working with three banks. We are simulating a number of scenarios. And we know that we are between these scenarios in our guidance. So we don't see any problem, as discussed in the prior earnings call. We apply hedging. So that's why, from a profitability point of view, we have limited impact on fluctuations regarding the rates we use. When we provide guidance, we don't disclose the rates; we provide the guidance, but we provide guidance at reported rates. And the scenario is the same. We work with three banks. We simulate something like 20 or 30 scenarios, and we are pretty sure that we are within those scenarios even today, even in Q2, with the appreciation of the Swedish kronor. Somehow, we were already anticipating it. And for that, the main impact has been in US dollars, where we have been impacted by 11 points quarter on quarter. So the Bricks are growing at a constant rate of approximately 32%. And the second impact is that we've seen effects in Australian dollars, British pounds, and euro, amounting to something around £6 per quarter on average. So that's a bit of the overview.

Fredrik Tiberg
41:21 - 41:33

Very clear. Thank you. Then maybe the second question on the PLD program. Um, do you already have some kind of idea what type of clinical endpoints you might be using in the upcoming Phase 3?

Jon Garay
41:35 - 41:54

Yes, we have an idea. And you know, they will likely reflect the endpoints, or at least some of the endpoints that we have been referring to today. But before going into that, we will await our end of phase two meeting with the FDA, which we are preparing for.

Richard Jameson
41:58 - 42:00

Okay. Thank you. That's all for me.

Fredrik Tiberg
42:01 - 42:07

The next question is from the analyst at ABG, Samuel Collier. Please go ahead here.

Jon Garay
42:10 - 42:35

Hi, this is George speaking. Thank you from Madison. Thank you for taking my questions. I have one left. So given the recent development of Brixadi sales, could you perhaps provide some insight into when we might expect the first sales milestones from Braeburn? And does this, to some extent, factor into your decision not to revise the 2025 guidance? Thank you.

Fredrik Tiberg
42:37 - 43:04

The information we have provided about the milestones indicates that there are three milestones at different sales levels, all of which fall within what we consider very reasonable sales levels. I don't think we have had any discussions. Would you like to comment on that, John, or is it, uh.

Jon Garay
43:04 - 43:17

No, we have not disclosed if our guidance includes milestones or not. We are working closely with everyone, and we need to see the sales performance in the second half of the year. And we will provide more information at the right time.

Fredrik Tiberg
43:20 - 43:27

So that's the amount of information that we have available at this moment. Are you okay with that, George?

Jon Garay
43:27 - 43:28

Okay. Thank you.

Fredrik Tiberg
43:29 - 43:30

Yes, thank you.

Jon Garay
43:30 - 43:36

The next question comes from Christine Glennie at Stifel. Please go ahead. Christiane, your line is open.

Richard Jameson
43:39 - 44:25

Hi guys. Thanks for taking the question. Follow up on a couple of points, please, just maybe around some data points. I guess, could you provide as much clarification as you can? So if we look at prescription data for Brixadi in the US, it's up about 14, 15%. But you've achieved nearly double that growth in terms of absolute sales. So is there something else going on here that might explain that disconnect? Are there other parts of the market, maybe things like CGS, getting better, or could there be some restocking going on here? Typically, you obviously see some destocking in Q1. Just trying to understand a bit of that disconnect or quite significant disconnect between what's showing in prescriptions versus what you're implying by your royalty number.

Fredrik Tiberg
44:26 - 45:47

Yeah, that's a very good question. So I mean, first of all, as we know, the numbers that count by IQ and other data providers. It is a limited data set and does not cover the full market, especially not specialty distributors. So that may be one source of the disconnect between the data provider numbers and the numbers that we provide. Then I should, of course, also comment on the fact that our numbers are from our partner. So we haven't got, you know, full detail into the actual sources of all growth drivers and whether or not there is a component of re-stocking or destocking in the data. Uh, I cannot, uh, comment on at this stage. We haven't had any signals of that. Uh, so, but I think the most important thing is that there is, generally speaking, a disconnect between the overall market and what is available through data providers.

Richard Jameson
45:51 - 46:13

Okay. Thank you. Has it improved through the second quarter? Do you think?

Fredrik Tiberg
46:15 - 46:40

I think, I think the effect has absolutely stabilized. But improvement is difficult to give you a view on right now. So can you give me a little bit more clarity into your question? And maybe I'm missing something. Oh, do you want.

Richard Jameson
46:40 - 46:41

To take one more round? You know, we understand that.

Fredrik Tiberg
46:44 - 47:03

So, I mean, I think the important thing is that on the federal level, we know financing has not improved as a consequence of the reduction that has disappeared. However, you know, at the state level, there is a large interest in the KGS sector.

Richard Jameson
47:08 - 47:48

Yeah. Fine. Thank you. And then another data point would be the minus five, uh, or 5%, uh, for oral buprenorphine in the second quarter. Um, again, look, as much as you can read across from IQVIA, oral products appear about flat in the second quarter. Obviously you're referencing some claims data. Again, is there anything that might explain it? Might be, might be different there in terms of the disconnect between those two. And are you seeing in that same claims data that the implication is Lee has taken that share, or is there something else that might explain that minus five?

Fredrik Tiberg
47:48 - 48:30

I mean, there is clearly a gain in share for Elias versus oral, at least in our data sets. Again, you know, there is quite a disconnect also between data providers and their coverage. So, I mean, I cannot say this is the data we are using. Um, it's possible that acquired data or whatever you are referring to is representative as well, or maybe even more representative. That's not for me to say. But our data supports a slight decrease, yet a better-stabilized situation compared to Q1.

Richard Jameson
48:35 - 48:37

Okay, thanks guys, I appreciate it.

Fredrik Tiberg
48:38 - 48:55

And before we go into the last questions, I'll just reconnect. We seem to have a short delay. So I reconnected the telco and we will move forward in a second. Now we are ready to take Richard Romanus' question from Read Out. Please go ahead. Your line is open.

Jon Garay
48:58 - 48:59

Good afternoon.

Richard Jameson
48:59 - 49:24

Afternoon. Will you have to do a phase three study after the phase one before approval for Cam 2029 PLD? Could you give us some more details about the timeline for the phase three study?

Fredrik Tiberg
49:26 - 50:37

Uh, well, I mean, on the first question, uh, we have not, uh. I mean, there are possibilities to go into a larger study very shortly after the initial, because this is really a phase one B study. However, we haven't announced anything, and we have a number of activities ongoing to further elaborate on that. Uh, when it comes to the second study on the PMD program, it will depend on the timeline and the amount of time that will be needed to secure the necessary data. So it will depend very much on the outcome with the regulatory authorities. So I think that's the extent of what we can communicate. Now, we will update on this in the next quarter or at least in the next half of the year as things get clearer. Um, instead of, um, speculating.

Richard Jameson
50:39 - 50:41

All right. Thank you.

Fredrik Tiberg
50:41 - 50:42

Uh, when it comes to the second study on the PMD program, it will depend on the timeline and the amount of time that will be needed to kind of secure the data. As you saw, there is a continued increase between placebo and active.

Richard Jameson
50:43 - 50:49

The next question is from Christopher, with a follow-up from Seb. Please go ahead, Christopher. Your line is open.

Fredrik Tiberg
50:50 - 51:21

Uh, hi. Thanks for taking my follow-ups. Uh, just so, um, obviously, we've had some news from the Trump administration. Uh, and I guess there's a little bit more clarity over the past quarter around Medicaid.

Jon Garay
51:22 - 52:31

So, I mean, Richard said that one of the important things is that the Medicaid percentage, at least to our understanding, remains unchanged. Uh, so that is a positive. And then there has been the work requirement, which, to my understanding, the 'big beautiful bill' kind of exempts the substance use disorder treatments from that requirement for the population. So that's also a positive. Um, then there is another detail on that. And that's the more frequent authorizations that would be required. But that's something that probably can be handled by. By the three, you know, which are the stakeholders involved in the treatment. So overall, I think that, you know, it looks quite positive in the context of, you know, the general political developments in the US.

Richard Jameson
52:33 - 53:03

Okay. That's, uh, very helpful. And then just one last question on the guidance, following up on Suzanne's question, which was about the 100 million milestone and the 150 million milestone being almost 50% or 40% or so of the range for pre-tax profit. Is it a fair assumption that without that you would have had to lower the pre-tax profit guidance?

Fredrik Tiberg
53:04 - 53:23

No, that's probably not a fair assumption. I would say that we haven't communicated whether or not the milestone was part of our original thinking. But, you could very well consider that, so. So, uh.

Richard Jameson
53:25 - 53:26

Okay. Thank you very much.

Fredrik Tiberg
53:29 - 53:34

There are no more questions from the telco at this time. So I hand the board back to you for closing comments.

Jon Garay
53:35 - 54:12

Okay. Thank you, everybody. It's been a pleasure today. And I'm sure everybody is looking forward to some relaxing weeks ahead. Before ending, I would just like to thank Jon for his contributions to these meetings over the years. And, uh, it's greatly appreciated. And we also welcome Anders. Of course, to take his place going forward. So, uh, great to have you. Thanks a lot. There are no more questions from the telco at this time.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…